Propel(x) is an angel investing platform focused on funding early-stage companies that are built around scientific discovery.  The company is driven by a mission to help propel mankind by enabling investments in technologies that matter.  Propel(x) was founded in 2014 and is headquartered in San Francisco, California.

Propel(X)

Dreamit Health is an accelerator investor which concentrates on health it, and medical device startups.

Dreamit Health

Mission Bay Capital is a venture capital firm for early-stage investments.

Mission Bay Capital

Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they are known by leaders of portfolio companies for the expertise and deep support they provide.

Mission BioCapital

Mayfield is a global venture capital firm with a people-first philosophy and a 50+ year track record of inception and investing, partnering with founders to build iconic enterprise, consumer, and engineering biology companies. Since its founding, the firm has invested in more than 500 companies, resulting in 119 IPOs and more than 200 acquisitions, and currently has $2.5B under management.

Mayfield Fund

Builders VC is an early-stage venture capital firm focused on investing where technology meets new business models to modernize antiquated industries including healthcare, agriculture, industrials and real-estate.

Builders VC

VSC Ventures is built on the core thesis that it has become easier than ever before to start a startup, but harder than ever before for that company to break out or get noticed.  Our award-winning comms firm has represented over 550 startups incl. 3 IPOs, 16 unicorns, and 50+ exits. Storytelling is our superpower. We’ll invest at Seed & Series A and go to work for you!

VSC Ventures

GraphWear Technologies

GraphWear is reinventing the way we map human health. Pioneering a no-needle, no-blood approach to disease monitoring, GraphWear’s technology offers the first genuinely non-invasive method to map patient health, unlocking a new adherence for some of the most significant chronic diseases. By empowering access to accurate and timely health information in an easy-to-use format, GraphWear aims to drive greater efficiency across diagnosis, management, and care. GraphWear is currently in clinical trials for its first target, monitoring glucose levels for diabetes, with additional potential across conditions like heart disease and cancer.

GraphWear develops a non-invasive continuous glucose monitor (CGM) system consisting of a small wearable sensor made of graphene—a single-atom thin carbon sheet that can conduct electricity. The electrical field attracts molecules near the surface of the skin when activated, without breaking the skin. The sensor measures glucose molecules using nanotechnology and the readings are then sent via Bluetooth to the company’s mobile app. Users can track their glucose levels over time and receive real-time alerts at specified levels. The device comes in as a wristwatch attachment or an adhesive patch for the abdomen.&nbsp;

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

GraphWear

<div>
 
 GraphWear develops a non-invasive continuous glucose monitor (CGM) system consisting of a small wearable sensor made of graphene&mdash;a single-atom thin carbon sheet that can conduct electricity. The electrical field attracts molecules near the surface of the skin when activated, without breaking the skin. The sensor measures glucose molecules using nanotechnology and the readings are then sent via Bluetooth to the company&rsquo;s mobile app. Users can track their glucose levels over time and receive real-time alerts at specified levels.
 
 
 The company built upon previous validation studies of the wearable, completing a pivotal trial and submitting for FDA clearance. The round was led by Mayfield, with participation from MissionBio Capital, Builders VC, and VSC Ventures.
 
 
 In October 2021, the company
 raised USD 20.5 million in Series B funding led by Mayfield which was directed toward its pivotal clinical trials to determine how accurately the system can measure glucose levels. The company also planned to expand its product offering to cater to conditions such as heart disease or cancer detection and grow its employee base.
 
</div>

GraphWear develops a non-invasive continuous glucose monitor (CGM) system consisting of a small wearable sensor made of graphene—a single-atom thin carbon sheet that can conduct electricity. The electrical field attracts molecules near the surface of the skin when activated, without breaking the skin. The sensor measures glucose molecules using nanotechnology and the readings are then sent via Bluetooth to the company’s mobile app. Users can track their glucose levels over time and receive real-time alerts at specified levels. The device comes in as a wristwatch attachment or an adhesive patch for the abdomen.&nbsp;Funding and financialsIn October 2021, the company raised USD 20.5 million in Series B funding led by Mayfield which was directed toward its pivotal clinical trials to determine how accurately the system can measure glucose levels. The company also planned to expand its product offering to cater to conditions such as heart disease or cancer detection and grow its employee base.

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

GraphWear

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless